Evidence for charged B meson decays to a1+/-(1260)pi0 and a1(0)(1260)pi+/-

We present measurements of the branching fractions for the decays B;{+/-}-->a_{1};{+/-}(1260)pi;{0} and B;{+/-}-->a_{1};{0}(1260)pi;{+/-} from a data sample of 232x10;{6} BB[over ] pairs produced in e;{+}e;{-} annihilation through the Upsilon(4S) resonance. We measure the branching fraction B(B;{+/-}-->a_{1};{+/-}(1260)pi;{0})xB(a_{1};{+/-}(1260)-->pi;{-}pi;{+}pi;{+/-})=(13.2+/-2.7+/-2.1)x10;{-6} with a significance of 4.2sigma, and the branching fraction B(B;{+/-}-->a_{1};{0}(1260)pi;{+/-})xB(a_{1};{0}(1260)-->pi;{-}pi;{+}pi;{0})=(20.4+/-4.7+/-3.4)x10;{-6} with a significance of 3.8sigma, where the first error quoted is statistical and the second is systematic.

Improved limits on the lepton-flavor violating decays tau{-}-->l{-}l{+}l{-}

A search for the neutrinoless, lepton-flavor violating decay of the tau lepton into three charged leptons has been performed using 376 fb{-1} of data collected at an e{+}e{-} center-of-mass energy around 10.58 GeV with the BABAR detector at the SLAC PEP-II storage rings. In all six decay modes considered, the numbers of events found in data are compatible with the background expectations. Upper limits on the branching fractions are set in the range (4-8)x10{-8} at 90% confidence level.

Measurement of CP violation parameters with a Dalitz plot analysis of B{+/-}-->D{pi{+}pi{-}pi{0}}K{+/-}

We report the results of a CP violation analysis of the decay B{+/-}-->D{pi{+}pi{-}pi;{0}}K{+/-}, where D{pi{+}pi{-}pi{0}} indicates a neutral D meson detected in the final state pi{+}pi{-}pi{0}, excluding K{S}{0}pi{0}. The analysis makes use of 324 x 10{6}e{+}e{-}-->BB[over ] events recorded by the BABAR experiment at the PEP-II e;{+}e;{-} storage ring. Analyzing the pi;{+}pi;{-}pi;{0} Dalitz plot distribution and the B{+/-}-->D{pi{+}pi{-}pi{0}}K{+/-} branching fraction and decay rate asymmetry, we find the following one-standard-deviation constraints on the amplitude ratio and on the weak and strong phases: 0.06<r{B}<0.78, -30 degrees <gamma<76 degrees , -27 degrees <delta<78 degrees . We also measure the magnitudes and phases of the components of the D{0}-->pi{+}pi{-}pi{0} decay amplitude.

Observation of B Meson decays to b1pi and b1K

We present the results of searches for decays of B mesons to final states with a b1 meson and a charged pion or kaon. The data, collected with the BABAR detector at the Stanford Linear Accelerator Center, represent 382x10(6) BB[over ] pairs produced in e+e- annihilation. The results for the branching fractions are, in units of 10(-6), B(B+-->b1(0)pi+)=6.7+/-1.7+/-1.0, B(B+-->b1(0)K+)=9.1+/-1.7+/-1.0, B(B0-->b1(-/+)pi(+/-))=10.9+/-1.2+/-0.9, and B(B0-->b1(-)K+)=7.4+/-1.0+/-1.0, with the assumption that B(b1-->omega pi)=1. We also measure charge and flavor asymmetries A(ch)(B+-->b1(0)pi+)=0.05+/-0.16+/-0.02, Ach(B+-->b1(0)K+)=-0.46+/-0.20+/-0.02, A(ch)(B0-->b1(-/+)pi(+/-))=-0.05+/-0.10+/-0.02, C(B0-->b1(-/+)pi(+/-))=-0.22+/-0.23+/-0.05, DeltaC(B0-->b1(-/+)pi(+/-))=-1.04+/-0.23+/-0.08, and A(ch)(B0-->b1(-)K+)=-0.07+/-0.12+/-0.02. The first error quoted is statistical, and the second systematic.

Measurement of cos2beta in B;{0}-->D;{(*)}h;{0} decays with a time-dependent Dalitz plot analysis of D-->K_{s};{0}pi;{+}pi;{-}

We study the time-dependent Dalitz plot of D-->K_{S};{0}pi;{+}pi;{-} in B;{0}-->D;{(*)}h;{0} decays, where h;{0} is a pi;{0}, eta, eta;{'}, or omega meson and D;{*}-->Dpi;{0}, using a data sample of 383x10;{6} Upsilon(4S)-->BB[over ] decays collected with the BABAR detector. We determine cos2beta=0.42+/-0.49+/-0.09+/-0.13, sin2beta=0.29+/-0.34+/-0.03+/-0.05, and |lambda|=1.01+/-0.08+/-0.02, where the first error is statistical, the second is the experimental systematic uncertainty, and the third, where given, is the Dalitz model uncertainty. Assuming the world average value for sin2beta and |lambda|=1, cos2beta>0 is preferred over cos2beta<0 at 86% confidence level.

Observation of the decay B+ --> K+K-pi+

We report the observation of charmless hadronic decays of charged B mesons to the final state K{+}K{-}pi{+}. Using a data sample of 347.5 fb{-1} collected at the Upsilon(4S) resonance with the BABAR detector, we observe 429+/-43 signal events with a significance of 9.6sigma. We measure the inclusive branching fraction B(B{+}-->K{+}K{-}pi{+})=[5.0+/-0.5(stat)+/-0.5(syst)]x10{-6}. Inspection of the Dalitz plot of signal candidates shows a broad structure peaking near 1.5 GeV/c{2} in the K+K- invariant mass distribution. We find the direct CP asymmetry to be consistent with zero.

Amplitude analysis of the B+/--->phiK*(892)+/- decay

We perform an amplitude analysis of B+/--->phi(1020)K*(892)+/- decay with a sample of about 384 x 10(6) BB[over ] pairs recorded with the BABAR detector. Overall, twelve parameters are measured, including the fractions of longitudinal fL and parity-odd transverse f perpendicular amplitudes, branching fraction, strong phases, and six parameters sensitive to CP violation. We use the dependence on the Kpi invariant mass of the interference between the JP=1(-) and 0+ Kpi components to resolve the discrete ambiguity in the determination of the strong and weak phases. Our measurements of fL=0.49+/-0.05+/-0.03, f perpendicular=0.21+/-0.05+/-0.02, and the strong phases point to the presence of a substantial helicity-plus amplitude from a presently unknown source.

Search for the Decay B+-->K+ tau-/+ mu+/-

We present a search for the lepton flavor violating decay B+-->K+ tau-/+ mu+/- using 383 x 10;{6} BB[over ] events collected by the BABAR experiment. The branching fraction for this decay can be substantially enhanced in new physics models. The kinematics of the tau from the signal B decay are inferred from the K+, mu, and other B in the event, which is fully reconstructed in one of a variety of hadronic decay modes, allowing the signal B candidate to be fully reconstructed. We observe no excess of events over the expected background and set a limit of B(B+-->K+ tau mu)<7.7 x 10(-5) at 90% confidence level, where the branching fraction is for the sum of the K+ tau- mu+ and K+ tau+mu- final states. We use this result to improve a model-independent bound on the energy scale of flavor-changing new physics.

Improved measurement of CP violation in neutral B decays to cc[over]s

We present updated measurements of time-dependent CP asymmetries in fully-reconstructed neutral B decays to several CP eigenstates containing a charmonium meson. The measurements use a data sample of (383+/-4)x10(6) Upsilon(4S)-->BB[over] decays collected with the BABAR detector at the PEP-II B factory. We determine sin2beta = 0.714+/-0.032(stat)+/-0.018(syst) and |lambda|=0.952+/-0.022(stat)+/-0.017(syst).

Measurements of CP-violating asymmetries in the decay B0-->K+K-K0

We analyze the decay B0-->K+K-K0 using 383 x 10(6) BB events collected by the BABAR detector at SLAC to extract CP violation parameter values over the Dalitz plot. Combining all K+K-K0 events, we find ACP=-0.015+/-0.077+/-0.053 and beta eff = 0.352+/-0.076+/-0.026 rad, corresponding to a CP violation significance of 4.8 sigma. A second solution near pi/2-beta eff is disfavored with a significance of 4.5 sigma. We also report ACP and beta eff separately for decays to phi(1020)K0, f0(980)K0, and K+K-K0 with mK+K- > 1.1 GeV/c2.

Measurement of the Time-Dependent CP Asymmetry in B;{0}-->D_{CP};{(*)}h;{0} Decays

We report a measurement of the time-dependent CP-asymmetry parameters S and C in color-suppressed B{0}-->D{(*)0}h{0} decays, where h{0} is a pi{0}, eta, or omega meson, and the decays to one of the CP eigenstates K+K-, K{S}{0}pi{0}, or K{S}{0}omega. The data sample consists of 383 x 10{6} Upsilon(4S)-->BB decays collected with the BABAR detector at the PEP-II asymmetric-energy B factory at SLAC. The results are S=-0.56+/-0.23+/-0.05 and C=-0.23+/-0.16+/-0.04, where the first error is statistical and the second is systematic.

Measurement of CP-violating asymmetries in B0-->D*(+/-)D(-/+)

We present updated measurements of CP-violating asymmetries in the decays B0-->D*(+/-)D(-/+) and B0-->D+D- using (383+/-4) x 10(6)B(B) pairs collected by the BABAR detector at the SLAC PEP-II B factory. We determine the time-integrated CP asymmetry A(D*(+/-)D(-/+))=0.12+/-0.06+/-0.02, and the time-dependent asymmetry parameters to be C(D*+D-)=0.18+/-0.15+/-0.04, S(D*+D-)=-0.79+/-0.21+/-0.06, C(D*-D+)=0.23+/-0.15+/-0.04, S(D*-D+)=-0.44+/-0.22+/-0.06, C(D+D-)=0.11+/-0.22+/-0.07, and S(D+D-)=-0.54+/-0.34+/-0.06, where the first uncertainty is statistical and the second is systematic.

Production and decay of Omegac0

We present an analysis of inclusive Omega(c)(0) baryon production and decays in 230.5 fb(-1) of data recorded with the BABAR detector. Omega(c)(0) baryons are reconstructed in four final states (Omega(-)pi(+), Omega(-)pi(+)pi(0), Omega(-)pi(+)pi(+)pi(-), Xi(-)K(-)pi(+)pi(+)) and the corresponding ratios of branching fractions are measured. We also measure the momentum spectrum in the e(+)e(-) center-of-mass frame. From the spectrum, we observe Omega(c)(0) production from B decays and in cc events, and extract the two rates of production.

Search for the rare decay B-->pil+ l-

We have performed a search for the flavor-changing neutral-current decays B-->pil+ l-, where l+ l- is either e+ e- or mu+ mu-, using a sample of 230 x 10(6) Upsilon(4S)-->BB decays collected with the BABAR detector. We observe no evidence of a signal and measure the upper limit on the isospin-averaged branching fraction to be B(B-->pil+ l-)<9.1 x 10(-8) at 90% confidence level. We also search for the lepton-flavor-violating decays B-->pie+/- mu-/+ and measure an upper limit on the isospin-averaged branching fraction of B(B-->pie+/- mu-/+)<9.2 x 10(-8) at 90% confidence level.

Observation of CP violation in B(0) --> K(+)pi(-) and B(0) --> pi(+)pi(-)

We report observations of CP violation in the decays B(0) --> K(+)pi(-) and B(0) --> pi(+)pi(-) in a sample of 383 x 10(6) Upsilon(4S) --> BB[over] events. We find 4372+/-82 B(0) --> K(+)pi(-) decays and measure the direct CP-violating charge asymmetry A(Kpi) = -0.107+/-0.018(stat)(-0.004)(+0.007)(syst), which excludes the CP-conserving hypothesis with a significance of 5.5 standard deviations. In the same sample, we find 1139+/-49 B(0) --> pi(+)pi(-) decays and measure the CP-violating asymmetries S(pipi) = -0.60+/-0.11(stat)+/-0.03(syst) and C(pipi) = -0.21+/-0.09(stat)+/-0.02(syst). CP conservation in B(0) --> pi(+)pi(-) (S(pipi) = C(pipi) = 0) is excluded at a confidence level 1-C.L. = 8 x 10(-8), corresponding to 5.4 standard deviations.

IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group

7649

Background: AZD2171 is an oral an inhibitor of the tyrosine kinase activity of all VEGFR subtypes. Objectives: To determine recommended phase II dose (RPTD), dose limiting toxicity (DLT), toxicity, pharmacokinetics and efficacy of AZD2171 with G/C, in pts with untreated ANSCLC. Methods: Eligibility: stage IIIB/IV NSCLC; PS 0–2; no prior chemotherapy (CT) for advanced disease; adequate hematological, biochemical and end-organ function; no significant hemoptysis or bleeding. Treated stable brain metastases were permitted. G 1,250 mg/m2 day 1 & 8 and C 80 mg/m2 day 1 was given q3 weekly with AZD2171 starting day 2 cycle 1. Planned dose levels (DL) of AZD2171 were 30 and 45 mg once daily PK assayed in cycle 1&2, response (RECIST) every 2nd cycle. Results: 14 pts enrolled. 30 mg (5 pts) and 45 mg (9 pts). Pt characteristics (n=13) median age 56; 11 PS 0–1; 9 males. No DLTs seen in initial 3 pts at 30 mg dose; nor in 9 pts at 45 mg dose. Actual median dose intensity for AZD2171 in cycle 1 (C1) was similar to planned in C1 for both DL (200 mg and 300 mg)), but was higher for 30 mg vs 45 mg for subsequent cycles (150 mg vs 134 mg). At the 45 mg DL 13 dose reductions occurred in 9 pts. Grade 3 adverse events occurred in 2 of 3 30 mg pts (1 hypertension (HT), 1 fatigue); at 45 mg 6 pts of 9 pts had grade 3 events (HT, fatigue, diarrhea, voice changes); 2 pts had grade 4 toxicity (1 reversible CNS ischemia, 1 fatigue). PK: no effect of AZD2171 on gemcitabine PK Objective response: 9 pts are evaluable (4 too early At 30 mg-PR 2, SD 1; at 45 mg-PR 3, SD 3. 2 additional patients were accrued at the 30 mg DL. Conclusions: Toxicities of this combination are manageable and predictable. HT was easily controlled with a standardized treatment algorithm. MTD was not reached at the 30 or 45mg dose level, but 30mg of AZD2171 appears better tolerated in combination with G/C and is suggested as the RPTD. Encouraging anti-tumor activity has been observed which does not appear dose dependent at the doses tested.

No significant financial relationships to disclose.

Anemia management with erythropoietic stimulating therapies (ESTs) in patients (pts) with gastrointestinal (GI) malignancies: Results from a prospective observational study

19614

Background: Chemotherapy-induced anemia is a common problem for pts with GI malignancies. To assess dosing patterns and outcomes in GI malignancy pts treated with ESTs (epoetin alfa (EPO) and darbepoetin alfa (DARB), a subset analysis of an ongoing registry was conducted. Methods: Data drawn between1/04 and 10/06 from 41 U.S. oncology clinics from the Dosing and Outcomes Study of Erythropoietic Stimulating Therapies (D.O.S.E.) registry were assessed. Pts were included in this analysis if they were diagnosed with a GI malignancy (colon, rectal, gastric, esophageal, or pancreatic), = 18 years, and received = 2 doses of either EPO or DARB. Outcomes assessed included mean baseline (BL) characteristics, transfusion utilization, hemoglobin (Hb) at Weeks 4, 8, and 12 after initiation of EPO or DARB, and cumulative EST doses with associated cost (based on 9/2006 wholesale acquisition cost). Results: 186 pts (82 EPO, 104 DARB) were identified. BL characteristics were similar between treatment groups: age 64 years, 45% women, and Hb 10.5g/dL. Both groups had a similar treatment duration (7 weeks) and number of Hb determinations (7.6); however, the DARB group had significantly more office visits (EPO 7, DARB 9.8, p=.0006). The proportion of pts transfused from Week 5 to end of study and number of units transfused/pt were similar between both groups. Hb values were similar at Weeks 4 (11.1 g/dL), 8 (11.1 g/dL), and 12 (11.0 g/dL). The mean administered dose per injection was 42,143 Units for EPO and 225 mcg for DARB. Mean cumulative administered dose during the treatment episode was 296,476 Units for EPO and 1,131 mcg for DARB, resulting in a dose ratio of 262:1 (Units EPO:mcg DARB). Overall EST cost was significantly lower in the EPO group compared to the DARB group (EPO $3,608, DARB $5,028, p=.0024). Conclusions: Similar hematological outcomes for EPO- and DARB-treated pts with GI malignancies were observed. Based on observed dosing patterns and cumulative EST utilization from this prospective observational study, EST costs were 28% lower in the EPO group than the DARB group. The observed dose ratio is consistent with previously reported clinical studies.

No significant financial relationships to disclose.

Hematologic outcomes of epoetin-alpha-treated cancer patients based on initial intervention of Hb <10 compared to Hb 10–11 g/dL: Results from a prospective observational study

19542

Background: Current guidelines recommend consideration of epoetin alfa (EPO) therapy for chemotherapy-induced anemia (CIA) when Hb <11 g/dL (National Comprehensive Cancer Network) or Hb < 10g/dL (ASCO/ASH). To evaluate clinical outcomes in EPO-treated patients initiated at Hb < 10 v. 10–11 g/dL, an analysis was conducted of clinical outcomes from practice settings. Data were analyzed from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) Registry, an ongoing, prospective registry collecting data on real-world practice patterns. Methods: Data from 29 U.S. hospital and community-based outpatient practices were assessed from 1/04–10/06. Chemotherapy-treated adult patients with a non-myeloid malignancy, baseline anemia (Hb < 11 g/dL), receipt of at least two EPO doses, and study completion were included. This analysis stratified patients based on Hb level at EPO initiation. Outcomes assessed included proportion of patients requiring RBC transfusion, mean treatment duration, and proportion of patients achieving an Hb = 11 g/dL. Results: 245 patients were eligible for analysis. 97 patients were initiated at a Hb < 10 g/dL and 148 patients were initiated at Hb 10–11 g/dL Baseline characteristics (age, gender distribution, weight, platinum-based therapy, Karnofsky score, primary tumor type) were similar except baseline Hb (9.4 g/dL v. 10.5 g/dL). Treatment duration was similar in both groups at approximately nine weeks. Transfusion outcomes and time to NCCN target Hb level (Hb =11 g/dL) are described in the table . Conclusions: This ongoing observational study demonstrated over two-thirds of patients achieved NCCN target Hb = 11 g/dL. Additional benefits for the patients initiated at Hb 10–11 g/dL were a shorter time to NCCN target Hb and a lower proportion of patients requiring transfusions. These results support the use of EPO for patients with chemotherapy-induced anemia and Hb < 11 g/dL.

[Table: see text]

No significant financial relationships to disclose.

A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens

6569

Background: New phase II trial designs have been proposed to accommodate the non-cytotoxic nature of molecularly targeted agents. In particular, the use of alternative endpoints and controls has been suggested. The objectives of this survey are to review the designs of contemporary phase II trials, to compare trials of cytotoxic versus non-cytotoxic regimens, and to identify predictors of acceptance for presentation. Methods: Abstracts of phase II trials of systemic anticancer therapy published in the 2005 ASCO Proceedings were hand searched. The trial context, type of intervention, trial design, endpoints, and completeness of reporting were assessed. Results: Our search yielded 565 abstracts: 72% were multi-center, 44% North American, 25% clearly identified as industry-sponsored, the median number of patients was 44 (range 8–346). Only 83% explicitly reported the study phase, 29% the primary endpoint, 11% the number of stages, and 5% the statistical design. For design properties, 16% used multiple arms and 6% used enrichment. Of trials reporting the primary endpoint, 48% used radiological or marker response and 22% time-to-event endpoints. The median number of endpoints was 4 (range 1–8). Non- cytotoxic regimens, which included targeted agents, hormone- or immunotherapy, constituted 22% of the trials reviewed, purely cytotoxic regimens 60%, the remaining 18% contained combinations of both. Trials of non-cytotoxic and combination regimens were more likely to report the primary endpoint (p=0.02), use time-to-event endpoints (p=0.006), have multiple arms, use enrichment, be conducted in North America, be industry-sponsored, and be accepted for oral or poster presentation (all p<0.001). Other predictors of publication type in multivariate analysis were multi-centricity, higher number of patients, industry involvement, and being conducted in North America (all p<0.05). Conclusions: Design properties of contemporary phase II trials of non-cytotoxic agents differ from trials of cytotoxic chemotherapy, and are more likely to be accepted for presentation at ASCO. Proposed new trial designs start to be more widely adopted. Most abstracts incompletely report design properties.

No significant financial relationships to disclose.

A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors

3576

Background: VOR (suberoylanilide hydroxamic acid; SAHA) is a small molecule inhibitor of histone deacetylase (HDAC) that binds directly to the enzyme’s active site in the presence of a zinc ion. Aberrant HDAC activity has been implicated in a variety of cancers. The combination of 5-fluorouracil and VOR is synergistic in preclinical tumor models. Methods: This phase I study evaluated safety, tolerability, and the recommended phase II dose (RPTD) of VOR and CAP in pts with advanced solid tumors. VOR was administered orally daily while CAP was administered orally bid on days 1–14 of a 21 d cycle. Results: Three dose levels have been evaluated (VOR (mg/d)/CAP (mg/bid)): 300/750, 300/1,000 and 400/1,000. Twenty-three pts have been treated: 6M/17F, median age 59 (range 41–73), ECOG 0:1:2 = 9:13:1, prior therapy 1:2:3 or more = 3:7:13. Pts had colorectal cancer (n=6), nasopharyngeal (n=3) and various other tumors. A total of 104 cycles have been administered, with median = 2 (range 1–15). One dose limiting toxicity (DLT) (grade 3 diarrhea) occurred in 6 patients at dose level 1. No DLT were observed at dose level 2, and 2 DLTs (grade 3 fatigue and grade 3 nausea/vomiting) occurred at dose level 3. RPTD was determined to be VOR 300 mg/d and CAP 1,000 mg/bid. Most common toxicities of any grade and at least possibly attributable (n=22) are: thrombocytopenia (59% of pts), fatigue (55%), nausea (55%), vomiting (50%), hypoalbuminemia (45%), anemia (41%), diarrhea (41%), anorexia (41%), elevated creatinine (36%), lymphopenia (36%), hyponatremia (36%), and hyperglycemia (36%). Common grade 3 toxicities included: hand-foot syndrome (23% of pts), diarrhea (14%), fatigue (14%), and lymphopenia (14%). One pt died on study from ventricular fibrillation due to sotalol and hypocalcemia from pre-existing hypoparathyroidism. Five patients with various tumor types had PR (2 confirmed, 3 unconfirmed) (2 nasopharyngeal, 1 each of ovarian, endometrial and squamous cell carcinoma of head and neck). In addition, disease stabilization was seen in 12 patients. Conclusions: VOR and CAP are well tolerated, and this combination is active in several tumor types. Further evaluations of VOR and CAP are warranted.

No significant financial relationships to disclose.

Hematologic outcomes and drug cost considerations of erythropoiesis stimulating agents (ESTs) in cancer patients (pts) with fixed dosing regimens: Results from practice patterns in a prospective observational study

17063

Background: The erythropoietic agents available today have FDA-approval for weight-based as well as fixed dosing in cancer pts with chemotherapy-induced anemia [epoetin alfa (EPO) 40,000 Units QW, darbepoetin alfa (DARB) 500 mcg Q3W]. To understand hematologic outcomes and EST cost considerations based on actual patterns of use, not protocol-driven use, data were analyzed from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) Registry, an ongoing registry of real-world practice. Methods: Data from 18 U.S. practice settings from 1/06–12/06 were assessed. Chemotherapy-treated adult cancer pts initiated at either EPO 40,000 Units or DARB 500 mcg were evaluated. Outcomes assessed included mean treatment duration, hematologic outcomes, mean administered dose, mean cumulative administered dose, and total EST cost (based on 9/2006 wholesale acquisition cost). Results: 168 pts (145 EPO, 23 DARB) were eligible. Patient groups were similar with regard to baseline age, gender distribution, tumor type, Karnofsky score and Hb. Treatment duration was similar for both agents, approximately 7 weeks. The proportion of pts transfused from Week 5 to end of study and number of units/ pt was not significantly different between groups (% transfused: EPO 10%, DARB 13%; Units/pt: EPO 0.2, DARB 0.3). Mean administered dose was 42,879 Units in the EPO group and 497 mcg in the DARB group. Mean cumulative administered dose for the treatment episode was 305,241 Units for EPO and 1,665 mcg for DARB, corresponding to an EST cost of $3,715 for EPO and $7,404 for DARB (p <.0001). Conclusions: Real-world practice pattern data from this observational study found similar treatment duration and transfusion patterns in the EPO-treated group versus the DARB-treated group in pts initiated with FDA-approved fixed dosing regimens. Cumulative EST cost was $3689 lower in the EPO group, a 50% reduction versus the DARB group.

No significant financial relationships to disclose.

A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors

14030

Background: Nimotuzumab (N) is a humanized mAb against the EGFR extracellular ligand binding domain. Although well tolerated when combined with radiotherapy in previous studies and lacking usual toxicities of EGFR-targeting agents, the pharmacodynamics (PD) of N has not been elucidated. This phase I study was designed to evaluate the safety, tolerability and PD of N. Methods: Eligibility criteria included advanced solid tumors refractory to standard therapy and ECOG PS = 0 - 2. IV N was administered weekly x 6 and then every other week (6 weeks = 1 treatment cycle). Tumor, skin and liver biopsies obtained pre- and 2 and 7 weeks post-treatment were evaluated using computer-based, whole mount assessment of immunohistochemical staining. Results: Accrual was completed 21/09/06, 17 patients (11m/6f, median age 63, 13 colorectal cancer, ECOG 0:1:2 = 6:10:1, prior therapy 1:2:3+ = 2:6:9) were registered and 16 patients were treated on 4 dose levels (100, 200, 400 and 800 mg) for a total of 43 treatment cycles (1 patient deemed ineligible after registration did not receive study therapy). Treatment was well tolerated. One dose-limiting toxicity was observed (dose level 1 - grade 3 fatigue possibly attributable to N) . Skin toxicity was mild (Gr 1/2 in 7/1 patients). Confirmed stable disease was seen in 6 patients, a confirmed partial response in 1 patient with prolonged progression-free status observed in 3 patients for 5.8, 14.1 and 18.7 months (the latter two remain on study). Baseline and week 2 biopsies of tumor/skin/liver were evaluable in 12/13/7 pts. Week 7 tumor/skin/liver biopsies in initially responding or stable patients were evaluable in 6/8/6 pts. Post treatment (week 2), EGFR staining decreased in 8/12 matched tumor [mean ratio (post/pre): 0.79 range: (0.37, 1.91)], 8/13 skin [0.96 (0.40, 1.31)] and 5/7 liver [0.88 (0.62, 1.17)] biopsies. No significant relationship was detected between pre/post-treatment EGFR expression with either response or toxicity. Evaluation of downstream targets of EGFR (in tumor, skin and liver) is ongoing and will be presented. Conclusions: Overall nimotuzumab was well tolerated and exhibits mild skin toxicity. Prolonged progression free-survival was observed in 3/16 of these heavily pre-treated patients.

No significant financial relationships to disclose.

Evidence of a broad structure at an invariant mass of 4.32 GeV/c2 in the reaction e+e- --> pi+pi-psi(2S) measured at BABAR

We present a measurement of the cross section of the process e(+)e(-)-->pi(+)pi(-)psi(2S) from threshold up to 8 GeV center-of-mass energy using events containing initial-state radiation, produced at the SLAC PEP-II e(+)e(-) storage rings. The study is based on 298 fb(-1) of data recorded with the BABAR detector. A structure is observed in the cross section not far above threshold, near 4.32 GeV. We also investigate the compatibility of this structure with the Y(4260) previously reported by this experiment.